Myriad Genetics, Inc. Sustainability Profile
Myriad Genetics, Inc., a leading player in the precision medicine industry, is headquartered in the United States. Founded in 1991, the company has established itself as a pioneer in genetic testing and molecular diagnostics, focusing on areas such as oncology, women's health, and hereditary cancer. With a commitment to advancing healthcare through innovative solutions, Myriad offers a range of unique products and services, including genetic tests that provide critical insights for personalised treatment plans. The company has achieved significant milestones, including the development of the first FDA-approved genetic test for breast cancer risk assessment. Recognised for its contributions to the field, Myriad Genetics holds a strong market position, continually striving to enhance patient outcomes through cutting-edge technology and research.
DitchCarbon Score
How does Myriad Genetics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Myriad Genetics, Inc.'s score of 25 is lower than 64% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Myriad Genetics, Inc.'s reported carbon emissions
In 2022, Myriad Genetics, Inc. reported total carbon emissions of approximately 686,600 kg CO2e, comprising 404,000 kg CO2e from Scope 1 emissions and 282,600 kg CO2e from Scope 2 emissions. This represents a significant reduction from 2021, where Scope 1 emissions alone were reported at 533,000,000 kg CO2e. Despite these figures, Myriad Genetics has not disclosed any Scope 3 emissions data, nor have they set specific reduction targets or initiatives under the Science Based Targets initiative (SBTi). The company has not made any climate pledges or commitments that are publicly available. As a US-based organisation, Myriad Genetics is part of a growing trend in the biotechnology sector to address climate change, although their current emissions data and lack of formal reduction targets suggest there is room for improvement in their climate commitments.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | |
|---|---|---|
| Scope 1 | 533,000,000 | 000,000 |
| Scope 2 | - | 000,000 |
| Scope 3 | - | - |
How Carbon Intensive is Myriad Genetics, Inc.'s Industry?
How Carbon Intensive is Myriad Genetics, Inc.'s Location?
Myriad Genetics, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Myriad Genetics, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
